Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues

Abstract

The present invention relates to a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders or diseases) of the gastrointestinal system. The method comprises administering to a subject in need thereof a therapeutically effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof. The growth hormone secretagogue can be co-administered with a laxative, a H 2 receptor antagonist, a serotonin 5-HT 4 agonist, an antacid, an opioid antagonist, a proton pump inhibitor, a motilin receptor agonist, dopamine antagonist, a cholinergic agonist, a cholinesterase inhibitor, somatostatin, octreotide, or any combination thereof.

1 - 75 . (canceled) 
     
     
         76 ) A method of treating post-operative ileus in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of ipamorelin or a pharmaceutically acceptable salt thereof. 
     
     
         77 ) The method of  claim 76  wherein said post-operative ileus is induced via opioid use and gastrointestinal surgery. 
     
     
         78 ) The method of  claim 76  comprising injection administration. 
     
     
         79 ) The method of  claim 76 , wherein said treatment consists essentially of said administration. 
     
     
         80 ) The method of  claim 76  comprising administration of from 0.01-2,600 mg of ipamorelin per day. 
     
     
         81 ) A method of stimulating gastrointestinal motility in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of ipamorelin or a pharmaceutically acceptable salt thereof. 
     
     
         82 ) The method of  claim 81  comprising injection administration. 
     
     
         83 ) The method of  claim 81  wherein said treatment consists essentially of said administration. 
     
     
         84 ) The method of  claim 81  comprising administration of from 0.01-2,600 mg of ipamorelin per day. 
     
     
         85 ) The method of  claim 81  wherein said patient is recovering from abdomen surgery. 
     
     
         86 ) The method of  claim 86  comprising administration of from 0.01-2,600 mg of ipamorelin per day. 
     
     
         87 ) The method of  claim 86  wherein said patient is recovering from abdomen surgery.